Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation

Bone Marrow Transplantation volume 26, pages 677–679 (2000)Cite this article

Abstract

Two patients with disseminated mantle-cell lymphoma relapsed 24 and 13 months, respectively, after high-dose chemotherapy and autologous stem cell transplantation (autoSCT). Both patients had an HLA-identical sibling and received an allogeneic stem cell transplant (alloSCT) 32 and 18 months after autologous transplant, after conditioning with fractionated 12 Gy total body irradiation plus cyclophosphamide 120 mg/kg. They are both alive and in complete remission 24 months after transplant. Both patients have developed chronic graft-versus-host disease and their Karnofsky performance status is 90%. AlloSCT may offer a useful approach in a subgroup of patients with mantle-cell lymphoma who have relapsed after autologous transplantation. Bone Marrow Transplantation (2000) 26, 677–679.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Banks PM, Chan J, Clearly ML et al. Mantle cell lymphoma: a proposal for unification of morphologic, immunologic, and molecular data Am J Surg Pathol 1992 16: 637–640

    Article  CAS  Google Scholar 

  2. Bosch F, Jares P, Campo E et al. PRAD1/Cyclin D1 gene overexpression in chronic lymphoprolypherative disorders: a highly specific marker of mantle cell lymphoma Blood 1994 84: 2726–2732

    CAS  PubMed  Google Scholar 

  3. Bosch F, López-Guillermo A, Campo E et al. Mantle cell lymphoma. Presenting features, response to therapy, and prognostic factors Cancer 1998 82: 567–575

    Article  CAS  Google Scholar 

  4. Shivdasani RA, Hess JL, Skarin AT et al. Intermediate lymphocytic lymphoma: Clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma J Clin Oncol 1993 11: 802–811

    Article  CAS  Google Scholar 

  5. Steward D, Vose J, Weisenburger D et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma Ann Oncol 1995 6: 263–266

    Article  Google Scholar 

  6. Khouri I, Romaguera J, Kartajian H et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma J Clin Oncol 1998 16: 3803–3809

    Article  CAS  Google Scholar 

  7. Freedman AS, Neuberg D, Gribben JG et al. High-dose chemo-radiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission J Clin Oncol 1998 16: 13–18

    Article  CAS  Google Scholar 

  8. Tsai T, Goodman S, Saez R et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation Bone Marrow Transplant 1997 20: 859–863

    Article  CAS  Google Scholar 

  9. de Lima M, van Besien KW, Giralt SA et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma Bone Marrow Transplant 1997 19: 121–127

    Article  CAS  Google Scholar 

  10. Fisher R, Dahlberg S, Nathwani B et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including mucosal-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study Blood 1995 85: 1075–1082

    CAS  Google Scholar 

  11. Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87–2 J Clin Oncol 1997 15: 1131–1137

    Article  CAS  Google Scholar 

  12. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New Engl J Med 1995 333: 1540–1545

    Article  CAS  Google Scholar 

  13. Verdonck LF, Dekker AW, Lokhorst HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma Blood 1997 90: 4201–4205

    CAS  PubMed  Google Scholar 

  14. van Biesen KW, de Lima M, Giralt SA et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect Bone Marrow Transplant 1997 19: 977–982

    Article  Google Scholar 

  15. Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation Blood 1991 77: 649–653

    CAS  PubMed  Google Scholar 

  16. Adkins D, Brown R, Goodnough LT et al. Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation Bone Marrow Transplant 1998 21: 97–99

    Article  CAS  Google Scholar 

  17. Corradini P, Ladetto M, Astolfi M et al. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma Br J Haematol 1996 94: 376–378

    Article  CAS  Google Scholar 

  18. Milpied N, Gaillard F, Moreau P et al. High-dose therapy with stem cell transplantation for mantle-cell lymphoma: results and prognostic factors, a single center experience Bone Marrow Transplant 1998 22: 645–650

    Article  CAS  Google Scholar 

  19. Barret AJ, Locatelli F, Treleaven JG et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favorable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party Br J Haematol 1991 79: 567–574

    Article  Google Scholar 

Download references

Acknowledgements

This work has been supported in part by grants SGR 1998/00111 from the Comissionat per a Universitats i Recerca (Generalitat Catalunya), and FISS-98/995 and 98/0380 from the Fondo de Investigaciones Sanitarias de la Seguridad Social, Spanish Ministry of Health. We wish to thank Anna Bauer for the English grammar review of the manuscript.

Author information

Authors and Affiliations

  1. Department of Hematology, Institute of Hematology and Oncology, Transplantation Unit, Postgraduate School of Hematology ‘Farreras-Valentí’, IDIBAPS, Hospital Clínic, University of Barcelona, Barcelona, Spain

    C Martínez, E Carreras, M Rovira, Á Urbano-Ispizua, J Esteve, M Perales, F Fernández & E Montserrat

Authors
  1. C Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Carreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Rovira
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Á Urbano-Ispizua
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Esteve
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Perales
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E Montserrat
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martínez, C., Carreras, E., Rovira, M. et al. Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation. Bone Marrow Transplant 26, 677–679 (2000). https://doi.org/10.1038/sj.bmt.1702567

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702567

Keywords

This article is cited by

Search

Advanced search

Quick links